Anushka Sharma, at 36, celebrated with ads, brands, and endorsements adgully.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from adgully.com Daily Mail and Mail on Sunday newspapers.
Mankind s new subsidiary will have an initial paid-up capital of Rs 5 crore with a further investment of up to Rs 250 crore in one or more tranches, the press statement added.
Mankind Pharma s gross margin fell due to inventory accruals and production capacity issues. Revenue growth driven by domestic business and exports. Consumer healthcare business undergoing turnaround with market share gains. Incremental gains expected in chronic therapies. Focus on secondary sales, rural penetration, flagship brands, and market share growth. Strengthening IT systems, strategic focus on user base, and product premiumization.
While there are no downside risks to Mankind’s earnings growth, pricey valuations also do not offer comfort. Moreover, one should be wary of the regulatory risks in the pharmaceutical sector, analysts say